Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regulatory issues in cellular therapies.

Adrian P Gee1

  • 1Center for Cell and Gene Therapy, Baylor College of Medicine Houston, Texas 77030, USA. apgee@txccc.org

Journal of Cellular Biochemistry. Supplement
|June 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental oxygen affects ex vivo growth and proliferation of mesenchymal progenitors by modulating mitogen-activated protein kinase and mammalian target of rapamycin signaling.

Cytotherapy·2022
Same author

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.

Blood·2022
Same author

The National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy.

Clinical and translational science·2021
Same author

A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.

European journal of heart failure·2021
Same author

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2021
Same author

Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial.

JACC. CardioOncology·2021
Same journal

Understanding immune cell trafficking patterns via in vivo bioluminescence imaging.

Journal of cellular biochemistry. Supplement·2003
Same journal

In vivo molecular imaging.

Journal of cellular biochemistry. Supplement·2003
Same journal

Introduction to the physics of molecular imaging with radioactive tracers in small animals.

Journal of cellular biochemistry. Supplement·2003
Same journal

Can small animal imaging accelerate drug development?

Journal of cellular biochemistry. Supplement·2003
Same journal

Advances in molecular labeling, high throughput imaging and machine intelligence portend powerful functional cellular biochemistry tools.

Journal of cellular biochemistry. Supplement·2003
Same journal

Grappling with metastatic risk: bringing molecular imaging of Met expression toward clinical use.

Journal of cellular biochemistry. Supplement·2003
See all related articles

The Food and Drug Administration is refining regulations for cellular and gene therapies. A patient death prompted a review of gene therapy rules, while cell therapy regulation now stratifies risk for donors and recipients.

Area of Science:

  • Biomedical Science
  • Regulatory Science
  • Therapeutic Development

Background:

  • Cellular and gene therapies represent promising new treatment modalities with significant therapeutic potential.
  • The rapid evolution of these fields necessitates adaptive regulatory strategies to balance innovation with patient safety.
  • Recent events, including a patient fatality in a gene therapy trial, have intensified regulatory scrutiny.

Purpose of the Study:

  • To review the history and current status of regulatory approaches for cellular and gene therapies.
  • To examine the Food and Drug Administration's evolving strategies for overseeing these advanced therapeutic fields.
  • To outline the emerging unified regulatory framework for cell-based therapies.

Main Methods:

  • Review of historical regulatory documents and agency communications.

Related Experiment Videos

  • Analysis of the Food and Drug Administration's strategic responses to safety concerns.
  • Examination of the risk-stratification model for cell-based therapy regulation.

    • Main Results:

    • The Food and Drug Administration is actively reassessing and developing regulatory frameworks for gene and cellular therapies.
    • A unified regulatory approach for cell-based therapies is being implemented, categorizing oversight based on donor and recipient risk.
    • The death of a patient underscored critical safety issues, prompting a comprehensive review of gene therapy regulations.

    Conclusions:

    • Regulatory oversight for cellular and gene therapies is adapting to ensure both scientific advancement and patient safety.
    • The risk-based stratification model offers a structured approach to regulating diverse cell-based therapies.
    • Continued vigilance and regulatory evolution are crucial for the responsible development of these transformative treatments.